Exhibit 10.7 OPTION AGREEMENT Option agreement dated as of March 5, 1999 between B. TWELVE, INC., a corporation existing under the laws of the State of Florida (the "Corporation") and DR. URI SAGMAN, an individual residing in the Province of Ontario...Option Agreement • August 22nd, 2002 • B Twelve Inc • Pharmaceutical preparations • Florida
Exhibit 10.14 TERMINATION AGREEMENT This Termination Agreement (the "Agreement") is made and entered into this 28th day of February, 2002, by and between The University of Texas M.D. Anderson Cancer Center ("UTMDACC"), a component institution of The...Termination Agreement • August 22nd, 2002 • B Twelve Inc • Pharmaceutical preparations • Texas
Exhibit 10.6 CONSULTING AGREEMENT BETWEEN: B TWELVE LIMITED (hereinafter referred to as the "Company")Consulting Agreement • July 31st, 2002 • B Twelve Inc • Pharmaceutical preparations • Ontario
EXHIBIT 10.13 AMENDMENT No. 1 TO RESEARCHResearch Agreement • August 22nd, 2002 • B Twelve Inc • Pharmaceutical preparations
AMENDED AND RESTATED UNANIMOUS SHAREHOLDERS' AGREEMENT Amended and restated unanimous shareholders' agreement dated January 15, 2001 among B. TWELVE, INC. (herein "B 12" or the "Corporation"), DR. URI SAGMAN ("Sagman"), CREDIFINANCE CAPITAL CORP....Shareholder Agreements • August 22nd, 2002 • B Twelve Inc • Pharmaceutical preparations • Florida
B TWELVE LIMITED. (hereinafter referred to as the "Company") -and- DR. URI SAGMAN (hereinafter referred to as the "Executive")Employment Agreement • July 31st, 2002 • B Twelve Inc • Pharmaceutical preparations • Ontario
AND ---Collaborative Research Agreement • September 20th, 2005 • Kyto Biopharma Inc • Pharmaceutical preparations
EXHIBIT 10.1 RESEARCH COLLABORATION AGREEMENT BETWEEN THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK AND B TWELVE LTD. AGREEMENT made this 19 day of August 1999 by and between THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, a...Research Collaboration Agreement • September 20th, 2005 • Kyto Biopharma Inc • Pharmaceutical preparations • New York
1. PROTOCOLSponsored Laboratory Study Agreement • August 22nd, 2002 • B Twelve Inc • Pharmaceutical preparations • Texas
CONVERTIBLE DEBENTURE - SERIES AConvertible Debenture • July 31st, 2002 • B Twelve Inc • Pharmaceutical preparations • Florida
EXTENSION/MODIFICATION RESEARCH COLLABORATION AGREEMENT BETWEEN THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK AND B TWELVE LTDResearch Collaboration Agreement • September 20th, 2005 • Kyto Biopharma Inc • Pharmaceutical preparations
EXHIBIT 10.4 THIS DEBT SETTELEMENT AGREEMENT AND PUT OPTION made the 19th day of November, 2002. BETWEEN: KYTO BIOPHARMAN, INC. (the "Corporation") a corporation incorporated under the laws of the State of Florida and previously known as B. Twelve, Inc.Debt Settlement Agreement • September 20th, 2005 • Kyto Biopharma Inc • Pharmaceutical preparations • New York
Exhibit 10.18 SECURITY AGREEMENT THIS SECURITY AGREEMENT (the "Security Agreement") is made as of May 1, 2002, by and between B. TWELVE, INC., a Florida corporation (the "Corporation"), and CREDIFINANCE GESTION S.A., a Switzerland corporation...Security Agreement • July 31st, 2002 • B Twelve Inc • Pharmaceutical preparations • Florida
SERVICES AGREEMENT BETWEEN:Services Agreement • November 18th, 2004 • Kyto Biopharma Inc • Pharmaceutical preparations • Florida
PLATFORM TECHNOLOGY, PATENT AND PATENT APPLICATION ASSIGNMENT AGREEMENTPatent Assignment Agreement • June 29th, 2012 • Kyto Biopharma Inc • Pharmaceutical preparations • Florida
WHEREAS the Vendor: (i) is the owner of certain intellectual property rights relating to technology owned or developed by or for the Vendor, including the patents and patent applications (such inventions, patents and patent applications hereinafter being collectively referred to as the “Patent Rights”); (ii) is the owner of other intellectual property rights owned by the Vendor relating to such technology (hereinafter referred to as the “Related Intellectual Property”); and, (iii) may have an interest in such other patent applications and technology listed on the attached Schedule B (hereinafter referred to as the “Additional Intellectual Property”).
ARTICLE 1 INTERPRETATIONPrice Protection Agreement • July 31st, 2002 • B Twelve Inc • Pharmaceutical preparations • Florida
